PURPOSE: This study assessed differences in neuropathic symptoms between colorectal cancer (CRC) patients with and without diabetes. Moreover, we aimed to explore whether neuropathic symptoms could be explained by the receipt of chemotherapy as it was previously shown that cancer patients with diabetes less often receive chemotherapy. METHODS: Data from a cross-sectional study among CRC patients (2-11 years after diagnosis) was used. Data were collected by the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry which is linked to clinical data from the population-based Eindhoven Cancer Registry. Diabetes status was self-reported and neuropathic symptoms were measured with the European Organization for Research and Treatment of Cancer quality of life questionnaire-chemotherapy-induced peripheral neuropathy 20 (EORTC QLQ-CIPN20). RESULTS: Two hundred eighteen CRC patients with diabetes were matched on age and sex to 975 CRC patients without diabetes. After adjustments for cancer treatment including chemotherapy and other covariates, logistic regression models showed that CRC patients with diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands (odds ratio (OR) = 1.40; 95% confidence interval (CI) 1.00-1.94), tingling toes or feet (OR = 1.47; 95% CI 1.04-2.07), numbness in toes or feet (OR = 1.83; 95% CI 1.28-2.62), and erection problems among men (OR = 1.83; 95% CI 1.11-3.03) as compared to CRC patients without diabetes. No differences in cancer treatment were found between CRC patients with and without diabetes. CONCLUSION: CRC patients with diabetes experienced more neuropathic symptoms, regardless of cancer treatment, suggesting that diabetes itself rather than treatment with chemotherapy results in more neuropathic symptoms among cancer patients with diabetes compared to those without. IMPLICATIONS FOR CANCER SURVIVORS: Up to 39% of cancer survivors might expect mainly mild, neuropathic symptoms, with more symptoms among patients with co-occurring diabetes.
PURPOSE: This study assessed differences in neuropathic symptoms between colorectal cancer (CRC) patients with and without diabetes. Moreover, we aimed to explore whether neuropathic symptoms could be explained by the receipt of chemotherapy as it was previously shown that cancerpatients with diabetes less often receive chemotherapy. METHODS: Data from a cross-sectional study among CRCpatients (2-11 years after diagnosis) was used. Data were collected by the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry which is linked to clinical data from the population-based Eindhoven Cancer Registry. Diabetes status was self-reported and neuropathic symptoms were measured with the European Organization for Research and Treatment of Cancer quality of life questionnaire-chemotherapy-induced peripheral neuropathy 20 (EORTC QLQ-CIPN20). RESULTS: Two hundred eighteen CRCpatients with diabetes were matched on age and sex to 975 CRCpatients without diabetes. After adjustments for cancer treatment including chemotherapy and other covariates, logistic regression models showed that CRCpatients with diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands (odds ratio (OR) = 1.40; 95% confidence interval (CI) 1.00-1.94), tingling toes or feet (OR = 1.47; 95% CI 1.04-2.07), numbness in toes or feet (OR = 1.83; 95% CI 1.28-2.62), and erection problems among men (OR = 1.83; 95% CI 1.11-3.03) as compared to CRCpatients without diabetes. No differences in cancer treatment were found between CRCpatients with and without diabetes. CONCLUSION:CRCpatients with diabetes experienced more neuropathic symptoms, regardless of cancer treatment, suggesting that diabetes itself rather than treatment with chemotherapy results in more neuropathic symptoms among cancerpatients with diabetes compared to those without. IMPLICATIONS FOR CANCER SURVIVORS: Up to 39% of cancer survivors might expect mainly mild, neuropathic symptoms, with more symptoms among patients with co-occurring diabetes.
Authors: R K Ramanathan; M L Rothenberg; A de Gramont; C Tournigand; R M Goldberg; S Gupta; T André Journal: Ann Oncol Date: 2009-11-03 Impact factor: 32.976
Authors: Rachel R Huxley; Alireza Ansary-Moghaddam; Peter Clifton; Sebastien Czernichow; Christine L Parr; Mark Woodward Journal: Int J Cancer Date: 2009-07-01 Impact factor: 7.396
Authors: Edward W Gregg; Paul Sorlie; Ryne Paulose-Ram; Qiuping Gu; Mark S Eberhardt; Michael Wolz; Vicki Burt; Lester Curtin; Michael Engelgau; Linda Geiss Journal: Diabetes Care Date: 2004-07 Impact factor: 19.112
Authors: Kelly B Stein; Claire F Snyder; Bethany B Barone; Hsin-Chieh Yeh; Kimberly S Peairs; Rachel L Derr; Antonio C Wolff; Frederick L Brancati Journal: Dig Dis Sci Date: 2010-07 Impact factor: 3.199
Authors: M M J Zanders; L N van Steenbergen; H R Haak; H J T Rutten; J F M Pruijt; P M P Poortmans; V E P P Lemmens; L V van de Poll-Franse Journal: Diabet Med Date: 2013-06-28 Impact factor: 4.359
Authors: Floortje Mols; Johan Denollet; Adrian A Kaptein; Peter H M Reemst; Melissa S Y Thong Journal: J Psychosom Res Date: 2012-07-24 Impact factor: 3.006
Authors: Pauline A J Vissers; Louise Falzon; Lonneke V van de Poll-Franse; Frans Pouwer; Melissa S Y Thong Journal: J Cancer Surviv Date: 2015-10-01 Impact factor: 4.442